Preclinical Characterization of [ 225 Ac]Ac-AG1001, a Novel SSTR2 Antagonist Radiolabeled with Actinium-225 (EANM 2026) - Sep 29, 2026 - Abstract #EP-0177; "Despite the efficacy of Lu-177 DOTATATE, a subset of patients exhibits refractory disease. [225Ac]Ac-AG1001 demonstrates robust preclinical pharmacological profiles with high SSTR2-binding activity, desirable pharmacokinetics, potent anti-tumor efficacy and a favorable safety profile, supporting its progression into clinical development."
Preclinical • Solid Tumor • SSTR • SSTR2
|
|
S. Xu; X. Zhang; Z. Lu; X. Li; X. Huang; R. Shi; Q. Chen; X. Gu; X. Tang; G. Liu; M. Liao; T. Wu; D. Dai; X. Gan; X. Ye
|